Access Genetics

access-genetics.com

Access Genetics, LLC is a privately held Minnesota-based company founded in 2001 by Dr. Ronald McGlennen, an internationally recognized molecular diagnostics expert with over a decade of experience in implementing and developing molecular genetic laboratories. As a medical technology service company, we offer turnkey solutions to assist laboratories in the implementation of molecular genetic testing by recommending a tailored, cost-effective and state-of-the-art suite of hardware, software, prepackaged materials and supplies, process guides, custom tools, staff training, technical support, telemedicine interpretations, and other optional consultative services. This comprehensive service package makes Access Genetics unlike other companies in the genetic testing market that may only provide a piece of the testing puzzle.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

news image

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More

Cell and Gene Therapy

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

news image

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

news image

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More

Medical

INTEGRATED DNA TECHNOLOGIES OPENS NEW THERAPEUTIC MANUFACTURING FACILITY TO SUPPORT GROWING DEMAND IN GENOMIC MEDICINE

businesswire | October 19, 2023

news image

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. The milestone marks a significant achievement in the company’s 35-year-history—its entrance into the therapeutics spa...

Read More
news image

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More
news image

Cell and Gene Therapy

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More
news image

MedTech, Industrial Impact

ATUM ANNOUNCES LICENSING DEAL WITH CODIAK FOR LEAP-IN TRANSPOSASE TECHNOLOGY

ATUM and Codiak | January 25, 2023

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology...

Read More
news image

Medical

INTEGRATED DNA TECHNOLOGIES OPENS NEW THERAPEUTIC MANUFACTURING FACILITY TO SUPPORT GROWING DEMAND IN GENOMIC MEDICINE

businesswire | October 19, 2023

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. The milestone marks a significant achievement in the company’s 35-year-history—its entrance into the therapeutics spa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us